Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial-Reference-Cited by-同舟云学术

Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial

Published:2016-05 Issue:5 Volume:4 Page:361-371
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Ghofrani Hossein-Ardeschir,Grimminger Friedrich,Grünig Ekkehard,Huang Yigao,Jansa Pavel,Jing Zhi-Cheng,Kilpatrick David,Langleben David,Rosenkranz Stephan,Menezes Flavia,Fritsch Arno,Nikkho Sylvia,Humbert Marc

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference35 articles.

1. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

2. Pulmonary arterial hypertension: epidemiology and registries;McGoon;J Am Coll Cardiol,2013

4. Five-year outcomes of patients enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension (PAH) disease management (REVEAL);Farber;Chest,2015

5. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension;Humbert;Eur Respir J,2010

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials;The Journal of Heart and Lung Transplantation;2024-09

3. Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension (2023);Eurasian heart journal;2024-03-11

4. Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis;Rheumatology;2024-03-09

5. The nitric oxide–soluble guanylate cyclase–cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase;European Respiratory Review;2024-01-31